An announcement from BioHarvest Sciences ( (TSE:BHSC) ) is now available.
BioHarvest Sciences has announced that its flagship product, VINIA, has surpassed $50 million in sales, with significant growth achieved since its US launch in 2021. The company plans to expand its production capacity fourfold to meet demand, highlighting VINIA’s positive reception and BioHarvest’s strategic growth trajectory in the nutraceutical industry.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a company specializing in the development of plant-based compounds using its patented Botanical Synthesis technology. Their primary product, VINIA, is a nutraceutical supplement made from red grape cell composition, which targets the health and wellness market, particularly focusing on heart health.
YTD Price Performance: -9.66%
Average Trading Volume: 1,209
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$137.8M
For an in-depth examination of BHSC stock, go to TipRanks’ Stock Analysis page.